MECP2 and depressive symptom measurement: The mechanism underlying the pharmacological effect of fluoxetine in treating poststroke depression involves upregulation of BDNF by separating the MeCP2–CREB–BDNF promoter IV complex via protein kinase A (PKA)-induced phosphorylation of MeCP2 at Ser421 [137].